Jazz' Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy
Shots:
- NICE has issued a positive Final Appraisal Document which recommends Sunosi (75/150mg, qd) as an option treatment for adults with EDS caused by narcolepsy with/out cataplexy. The therapy will be available in England and Wales
- The recommendation is based on the P-III TONES studies to evaluate Sunosi vs PBO in adults patients with EDS. The results demonstrated a clinical effectiveness and safety profile of solriamfetol in patients with narcolepsy & maintain its effect after 6mos. of treatment
- Solriamfetol is dual-acting dopamine and noradrenaline reuptake inhibitor & is designed to improve wakefulness and reduce EDS in adult patients with narcolepsy
Ref: Jazz | Image: Jazz
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com